Inozyme Pharma (NASDAQ:INZY) Stock Rating Upgraded by Wall Street Zen

Inozyme Pharma (NASDAQ:INZY - Get Free Report) was upgraded by research analysts at Wall Street Zen to a "sell" rating in a research note issued on Saturday.

INZY has been the subject of several other research reports. HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of Inozyme Pharma in a research report on Thursday, April 10th. Wedbush downgraded shares of Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th. Jefferies Financial Group reissued a "hold" rating and set a $4.00 price target (down previously from $15.00) on shares of Inozyme Pharma in a report on Friday, May 16th. TD Cowen cut Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th. Finally, Needham & Company LLC cut Inozyme Pharma from a "moderate buy" rating to a "hold" rating in a research report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $11.75.

Inozyme Pharma Stock Performance

Shares of INZY remained flat at $4.00 during midday trading on Friday. Inozyme Pharma has a 52-week low of $0.72 and a 52-week high of $6.24. The company has a quick ratio of 2.19, a current ratio of 2.19 and a debt-to-equity ratio of 0.65. The company has a market cap of $258.25 million, a price-to-earnings ratio of -2.37 and a beta of 2.27. The company's 50-day simple moving average is $3.33 and its 200-day simple moving average is $2.08.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01). As a group, equities analysts anticipate that Inozyme Pharma will post -1.59 earnings per share for the current year.

Institutional Investors Weigh In On Inozyme Pharma

A number of institutional investors have recently added to or reduced their stakes in INZY. Affinity Asset Advisors LLC lifted its holdings in shares of Inozyme Pharma by 40.7% in the 4th quarter. Affinity Asset Advisors LLC now owns 3,972,318 shares of the company's stock valued at $11,003,000 after buying an additional 1,150,000 shares during the period. Rock Springs Capital Management LP raised its position in Inozyme Pharma by 1.6% in the fourth quarter. Rock Springs Capital Management LP now owns 3,861,983 shares of the company's stock worth $10,698,000 after acquiring an additional 59,100 shares in the last quarter. Millennium Management LLC lifted its holdings in Inozyme Pharma by 7.9% in the fourth quarter. Millennium Management LLC now owns 1,882,274 shares of the company's stock valued at $5,214,000 after acquiring an additional 137,821 shares during the period. Geode Capital Management LLC lifted its holdings in Inozyme Pharma by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 1,179,622 shares of the company's stock valued at $3,268,000 after acquiring an additional 8,450 shares during the period. Finally, Knott David M Jr boosted its position in shares of Inozyme Pharma by 23.1% during the 4th quarter. Knott David M Jr now owns 695,000 shares of the company's stock worth $1,925,000 after purchasing an additional 130,451 shares in the last quarter. Hedge funds and other institutional investors own 88.30% of the company's stock.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.